Cardiovascular Risk and Inflammation: Pathophysiological Mechanisms, Drug Design, and TargetsGASPARYAN, Armen Yuri.Current pharmaceutical design (Print). 2012, Vol 18, Num 11, issn 1381-6128, 110 p.Serial Issue

Rheumatoid Arthritis: Cardiovascular Manifestations, Pathogenesis, and TherapyMELLANA, William M; ARONOW, Wilbert S; PALANISWAMY, Chandrasekar et al.Current pharmaceutical design (Print). 2012, Vol 18, Num 11, pp 1450-1456, issn 1381-6128, 7 p.Article

Inflammation-Induced Thrombosis: Mechanisms, Disease Associations and ManagementAKSU, Kenan; DONMEZ, Ayhan; KESER, Gokhan et al.Current pharmaceutical design (Print). 2012, Vol 18, Num 11, pp 1478-1493, issn 1381-6128, 16 p.Article

Inflammation and Vascular Responses to Acute Mental Stress: Implications for the Triggering of Myocardial InfarctionPAINE, Nicola J; BOSCH, Jos A; VELDHUIJZEN VAN ZANTEN, Jet J. C. S et al.Current pharmaceutical design (Print). 2012, Vol 18, Num 11, pp 1494-1501, issn 1381-6128, 8 p.Article

The Effect of Anti-B-cell Therapy on the Development of Atherosclerosis in Patients with Rheumatoid ArthritisNOVIKOVA, Diana S; POPKOVA, Tatyana V; NASONOV, Eugeny L et al.Current pharmaceutical design (Print). 2012, Vol 18, Num 11, pp 1512-1518, issn 1381-6128, 7 p.Article

Statins as Anti-Inflammatory Agents in Atherogenesis: Molecular Mechanisms and Lessons from the Recent Clinical TrialsANTONOPOULOS, Alexios S; MARGARITIS, Marios; LEE, Regent et al.Current pharmaceutical design (Print). 2012, Vol 18, Num 11, pp 1519-1530, issn 1381-6128, 12 p.Article

Systemic Sclerosis-Related Pulmonary Hypertension: Unique Characteristics and Future Treatment TargetsDIMITROULAS, Theodoros; GIANNAKOULAS, Georgios; KARVOUNIS, Haralambos et al.Current pharmaceutical design (Print). 2012, Vol 18, Num 11, pp 1457-1464, issn 1381-6128, 8 p.Article

Excess Cardiovascular Risk in Inflammatory Rheumatic Diseases: Pathophysiology and Targeted TherapyONAT, Altan; DIRESKENELI, Haner.Current pharmaceutical design (Print). 2012, Vol 18, Num 11, pp 1465-1477, issn 1381-6128, 13 p.Article

The Effects of Tumor Necrosis Factor Inhibitors on Cardiovascular Risk in Rheumatoid ArthritisPETERS, Mike J. L; SIJL, Alper M. Van; VOSKUYL, Alexandre E et al.Current pharmaceutical design (Print). 2012, Vol 18, Num 11, pp 1502-1511, issn 1381-6128, 10 p.Article

Adverse Cardiovascular Effects of Antirheumatic Drugs: Implications for Clinical Practice and ResearchYURI GASPARYAN, Armen; AYVAZYAN, Lilit; COCCO, Giuseppe et al.Current pharmaceutical design (Print). 2012, Vol 18, Num 11, pp 1543-1555, issn 1381-6128, 13 p.Article

Marine n-3 Fatty Acids for Cardiovascular Risk Reduction and Disease Control in Rheumatoid Arthritis: Kill Two Birds with One Stone?RONTOYANNI, Victoria G; SFIKAKIS, Petros P; KITAS, George D et al.Current pharmaceutical design (Print). 2012, Vol 18, Num 11, pp 1531-1542, issn 1381-6128, 12 p.Article